Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

Soreskog E.; Lindberg I.; Kanis J. A.; Akesson K. E.; Willems D.; Lorentzon M.; Strom O.; Berling P.; Borgstrom F.

首页> 外文期刊>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA >Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

【24h】

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

机译：罗米氏菌属治疗瑞典骨折高风险骨质疏松症治疗绝经后妇女的成本效果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture.

机译：罗莫佐单抗是一种新型的造骨药物，可降低骨折风险。这项健康经济分析表明，罗莫单抗与阿仑膦酸钠序贯治疗绝经后严重骨质疏松症合并骨折风险高的妇女是一种经济有效的治疗选择。

著录项

来源
《Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA》 |2021年第3期|共10页
作者
Soreskog E.; Lindberg I.; Kanis J. A.; Akesson K. E.; Willems D.; Lorentzon M.; Strom O.; Berling P.; Borgstrom F.;
展开▼
作者单位

Quantify Res Stockholm Sweden;

Quantify Res Stockholm Sweden;

Univ Sheffield Sheffield S Yorkshire England;

Lund Univ Skane Univ Hosp Malmo Sweden;

UCB Pharma Brussels Belgium;

Australian Catholic Univ Mary MacKillop Inst Hlth Res Melbourne Vic Australia;

Quantify Res Stockholm Sweden;

UCB Pharma Stockholm Sweden;

Quantify Res Stockholm Sweden;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类骨科学（运动系疾病、矫形外科学）;
关键词
Cost-effectiveness; Economic evaluation; Imminent fracture risk; Markov-microsimulation model; Osteoporosis; Recent fracture;

机译：成本效益;经济评价;即将发生骨折的风险;马尔可夫微观模拟模型;骨质疏松症;新近骨折;

相似文献

外文文献
中文文献
专利

1. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis [J] . Liu Yi, Liu Haijuan, Li Mei, 中华医学杂志（英文版） . 2014,第004期
2. The clinical value of BALP on diagnosis and treatment of osteoporosis in postmenopausal women [J] . Weiguo Li, Hua Lin, Yong Qiu, 生物医学研究杂志（英文版） . 2006,第006期
3. Effect of regular anti-osteoporosis treatment on bone mineral density and bone metabolism in patients with primary osteoporosis and its relationship with bone fractures [J] . Xue-Feng Qian, Ping Cao, Shuan Liu, 海南医科大学学报（英文版） . 2016,第024期
4. Romosozumab-aqqg (Evenity) for Osteoporosis in Postmenopausal Women at High Risk for Fracture [J] . P & T: a peer-reviewed journal for formulary management . 2019,第11期

机译：骨折骨折骨质疏松症（Evensity）的罗米苏酶骨质疏松症的高风险骨折
5. The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study [J] . Piet Geusens, Mary Oates, Akimitsu Miyauchi, JBMR plus. . 2019,第10期

机译：1年romoSozuab对骨质疏松症绝胡因妇女临床椎体骨折发病率的影响：框架研究的结果
6. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis [J] . Anne Sophie Koldkj?r S?lling, Torben Harsl?f, Bente Langdahl Therapeutic advances in musculoskeletal disease. . 2018,第5a6期

机译：罗莫唑单抗预防绝经后骨质疏松妇女骨折的临床潜力
7. Modeling the risk of osteopenia and osteoporosis in postmenopausal women with type 2 diabetes on the sets of clinical and immunogenetic parameters [C] . O. N. Fazullina, V. V. Klimontov, V. I. Konenkov, 2017 International Multi-Conference on Engineering, Computer and Information Sciences . 2017

机译：根据临床和免疫遗传学参数对绝经后2型糖尿病妇女骨质疏松和骨质疏松的风险进行建模
8. An assessment of risk factors and attitude toward physical activity in postmenopausal women committed to an osteoporosis related research project. [D] . Hammond, Judy Oliver. 1991

机译：致力于骨质疏松症相关研究项目的绝经后妇女的危险因素和对体育活动态度的评估。
9. OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis [O] . Robert Feldman, Piet Geusens, Mary Oates, 2020

机译：OR13-05 RomoSozumab治疗降低了骨质疏松症绝经妇女所有骨折严重程度的新椎骨骨折的发生率
10. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden [O] . E. Söreskog, I. Lindberg, J.A. Kanis, 2021

机译：罗姆索唑治疗瑞典骨折风险严重骨质疏松症治疗绝经后妇女的成本效果
11. Risk Factors for Osteoporosis and Oral Bone Loss in Postmenopausal Women. [R] . Wactawski-Wende, J. 2001

机译：绝经后妇女骨质疏松症和口腔骨丢失的危险因素。

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

摘要

著录项

相似文献

相关主题

期刊订阅